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1. INTRODUCTION 
Human milk protects the immunologically im- 
mature infant from gastro-intestinal invasion of 
pathogenic microbes by providing significant 
quantities of 3 proteins: sIgA, LF, and Lys [l-4]. 
sIgA and LF constitute - 5% each of the total milk 
protein, while Lys represents < 0.5% [l]. LF, a 
75 000-80 000 Mr single polypeptide chain [5], 
binds 2 atoms of ferric iron with a K1 260 x larger 
than that of serum transferrin [6]. By sequestering 
iron so strongly, LF acts to deprive the gut flora of 
the free iron required for proliferation and is 
strongly bacteriostatic in vitro for many common 
gut-associated pathogens [7,8]. Lys (EC 3.2.1.17; 
N-acetylmuramide glycanohydrolase) is an enzyme 
which hydrolyzes the glycosidic bonds between 
N-acetylglucosamine and N-acetylmuramic acid, 
components of the bacterial cell wall peptidoglycan. 
Breast milk [Lys] are 3-10 mg% compared with 
serum levels of 0.6-l mg%, and the human milk 
enzyme [l] has been reported to have a specific 
activity 3.5 X that of egg white lysozyme [4]. The 
mechanism of its role in the defense of the infant 
gut from pathogens, yet to be fully explained, most 
probably is intricately interrelated with antibody 
and possibly complement components for full ef- 
fectiveness [9]. Our long-range purpose is to syste- 
matically study such concertive or synergistic rela- 
tionships involving host defense factors in human 
milk. Both LF and Lys represent very effective, 
however non-specific, antimicrobial activities. 
However, milk sIgA confers upon the infant specific 
antibacterial, antiviral, antitoxic antibodies [lo] re- 
flective of the spectrum of the mother’s antigenic 
experience. sIgA in milk is - 150 mg% [I]. The 
intake of specific antimicrobial antibodies is quite 
high throughout the nursing period thus providing 
passive immunity during the time in which the in- 
fant immune system is maturing. By mechanisms 
which are not yet clear, sIgA potentiates the anti- 
bacterial activity of LF 171. 
We describe here a protocol for sequential isola- 
tion of all 3 of these proteins from the same sample 
of pooled human milk. The very high isoelectric 
pH-values of Lys and LF enable them to be sepa- 
rated from the remainder of milk (whey) proteins 
and from each other in a single chromatographic 
separation on heparin-Sepharose, a technique 
described in [ 1 l] for the isolation of pure LF. From 
the remaining proteins, pure sIgA has been isolated. 
It is of great interest to begin to examine the factors 
in human milk which, both singly and in concert, 
protect against a battery of potential pathogens. 
2. MATERIALS AND METHODS 
Abbreviations: sIgA, secretory immunoglobulin A; LF, 
lactoferrin; Lys, lysozyme; HS, heparin-Sepharose. 
* Address reprint requests to Department of Microbio- 
‘08Y 
Human milk was obtained from the Neonatal 
Intensive Care Unit (University of Missouri Health 
Sciences Center, Columbia MO). Aliquots of indi- 
vidual samples were taken and pools were made of 
milk from at least 6 mothers. The milk was stored 
frozen at - 20°C in 500 ml aliquots. Hepa- 
rin-Sepharose and Sephadex filtration gels were 
obtained from Pharmacia (Uppsala). Monospecific 
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antisera to human LF (rabbit) and s&A (goat) were 
obtained from Behring Diagnostics and Cappel 
Laboratories, respectively. Rabbit anti-serum 
against whole milk proteins was obtained from 
Nordic Immunological Laboratories. Dried Micro- 
coccus lysodeikticus was obtained from Sigma. 
Protein concentrations were determined as in [ 121 
using crystalline bovine serum albumin as a stan- 
dard. SDS-polyacrylamide gel electrophoresis was 
done as in 1131. Lys activity was quantitated spec- 
trophotometrically [ 141 using heat-killed M. lyso- 
deikticus. Large numbers of column fractions were 
screened for Lys activity using the lysoplate method 
[ 151 at pH 6.3 using egg white lysozyme as standard. 
Dialysis of whey prior to HS chromatography was 
done in Spectrapor dialysis tubing (Spectrum 
Medical Industries) with an -3500 M, cut off to 
prevent loss of Lys. Pressure concentrations of 
Lys fractions was done on Amicon UM2 mem- 
branes and all other fractions on Amicon PM30. 
3. RESULTS AND DISCUSSION 
Pooled human milk was thawed at room tempe- 
rature and the cream removed by centrifuging at 
10 000 x g for 30 min. All procedures were carried 
out at 4°C except where noted. The resultant skim 
milk was adjusted to pH 4.7 with 4 N HCl and 
incubated at 40°C for 30 min to precipitate predo- 
minantly the caseins. After centrifugation as above, 
the whey was decanted and the precipitate redis- 
solved in 0.1 M Tris-HCl buffer (pH 7.5) containing 
0.1 M NaCl. The latter was frozen at - 20°C and 
was used to estimate the amount of sIgA, Lys and 
LF lost at this step. A simplified flow diagram of the 
subsequent whey fractionation is shown below: 
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Fig. 1. Heparin-Sepharose chromatography of 3 10 ml 
human whey in 0.005 M Veronal-HCl (pH 7.4), 0.05 M 
NaCl followed by a linear 0.05-1.0 M NaCl gradient. 
Flow rate was 20 ml/h. Of the total of 2864 mg which was 
loaded on the column, 1768, 260, 19 and 350 mg were 
recovered after concentration from pools 1, 2, 3 and 4, 
respectively. 
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Fig.2. Sephadex G-75 gel filtration of HS-3 in 0.1 M 
sodium acetate (pH 6.5). Flow rate was 20 ml/h. The 
protein load was 37 mg protein representing -600 ml 
whey from which 8 mg pure lysozyme was recovered after 
concentration. This separation was very reproducible 
with the size of the first peak varying with the degree of 
contamination with LF. Every attempt was made to pool 
fractions containing high enzyme activity into HS-3 
rather than following the UV elution pattern. 
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Whey was dialyzed against 3 changes of a 10 X 
vol. 0.05 M NaCl in 0.005 M Verona1 HCl (pH 7.4). 
HS chromatography essentially followed the 
method in [ 111. Fig.1 shows a representative 
fractionation of 310 ml whey on a 2 cm x 30 cm 
column of HS. HS- 1 contains all the whey proteins 
not basic enough to have affinity for the strongly 
negatively charged heparin moiety. This peak 
usually contains all of the sIgA; however, with some 
milk pools, a slight amount may be retained and 
elute off with relatively low molarity NaCl in HS-2. 
The first peak contains no LF and only 5-7% of the 
total Lys activity which is probably loosely complexed 
with acidic proteins. After washing the column 
with starting buffer, a linear 800 ml gradient from 
0.05- 1.0 M NaCl was initiated at a relatively slow 
flow rate of 20 ml/h. HS-2, HS-3 and HS-4 eluted 
with - 0.2 M, 0.4 M, and 0.6 M NaCl, respectively. 
HS-3 contained most of the Lys activity applied to 
the column and HS-4 contained all of the LF. At 
this point, LF was essentially pure. However it 
could be recycled on HS to eliminate any trace 
contaminants such as lysozyme. About 350 mg pure 
LF was obtained from 3 10 ml whey. 
All HS fractions prior to pooling were tested im- 
munochemically for the presence of sIgA, LF and, 
using the lysoplate method, Lys activity. Pools were 
then assayed spectrophotometrically for Lys activi- 
ty: 72% of the Lys activity in the starting whey was 
contained in HS-3. After concentration, HS-3 was 
gel filtered on a 2.5 cm X 90 cm Sephadex G-75 
column since the predominant contaminants were 
of much higher M,-value. A symmetrical peak, 
eluted in the small size region (see fig.2) contained 
all the Lys activity. The yield of lysozyme protein 
was l- 1.5 mg lysozyme protein/ 100 ml whey. 
sIgA was purified from HS-1 in a 2-step proce- 
dure following the method in [ 161. The HS- 1 pool was 
Fig.3. 12.5% SDS-polyacrylamide gel electrophoresis under reducing conditions of: whey 10 pl(3), s&A 30 pg (6), 
LF 25 pg (7), Lys 20 pg (2,4), and Bio-Rad low-M, standards (1,5,8). 
3 
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concentrated 2-fold to 250 ml, dialyzed against 0.0 1 
M sodium phosphate (pH 7.0) and applied to a 150 
ml bed vol. column of DEAE-cellulose (DE 52) 
equilibrated with the same buffer. The column was 
pumped at -50 ml/h until the first peak was 
completely eluted and baseline was maintained for 
at least 2 column vol. The bulk of the s&A eluted 
with 0.1 M NaCl in the same buffer. Of the 1.7 g 
protein applied to this column, the peak eluting 
with starting buffer contained only - 1% of the 
protein. The second peak contained 300-350 mg 
total; however, only those fractions containing sIgA 
were pooled and concentrated for subsequent gel 
filtration. A similar separation was done using a 440 
ml bed vol. column of DE52 with twice the length. 
The first peak was again only - 1% of the protein 
while second peak region, even though bulk eluted, 
clearly resolved into 2 peaks, the first of which 
contained all the sIgA (- 130 mg) while the second 
contained predominantly and unidentified protein 
which was similar in size to, but was not, lysozyme. 
Regardless of which column size was used, sIgA was 
obtained pure from the subsequent gel filtration. 
After concentration, the sIgA-containing pool, still 
< 50% pure, was gel filtered at 20 ml/h on a 2.5 cm 
x 90 cm Sephadex G-200 column in 0.05 M 
Tris-HCl (pH 7.5) containing 0.2 M NaCl, 0.00 1 M 
EDTA and 0.003 M sodium azide. The resultant 
first peak contained pure sIgA with no detectable 
lysozyme activity. About 0.4 mg/ml whey were re- 
covered. 
LF, Lys and sIgA, prepared as described, were 
shown to be pure by electrophoresis in 12% 
SDS-polyacrylamide gels (lig.3). LF was a single 
protein band of -78 000 Mr. Lys also showed a 
single band approximately the size of the egg white 
lysozyme standard (- 15 000 M,). sIgA under these 
reducing conditions separated into its component 
chains - secretory component, heavy and light 
chains, and J chain. In double gel diffusion using 
heterospecific antiserum to milk proteins both LF 
and s&A showed single precipitins and, using spe- 
cific anti-LF and anti-sIgA, no cross-contamination 
was demonstrable in the purified preparations of 
LF, Lys and sIgA (tig.4). The specific (i.e., units/ 
A& enzyme activity was identical in all the 
fractions contained in the Sephadex G-75 lysozyme 
peak, again demonstrating purity of the prepara- 
tion. Antisera are now being prepared to all 3 pro- 
teins for use in their quantitation during our 
4 
Fig.4. Ouchterlony double gel diffusion of whey (1,3,5), 
LF (2) Lys (4) and sIgA (6) against anti-whole milk (A), 
anti-LF (B) and anti-s&A (C). The additional precipitin 
line detected by anti-sIgA in whey represents a contami- 
nating antibody in the commercial antiserum used. This 
line is never seen with our purified s&A preparations. 
ensuing studies of these as host-defense factors in 
human milk. 
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